Canonical Fibroblast Growth Factor ligands (FGFs) (FGFs)

Canonical Fibroblast Growth Factor (FGF) ligands are a group of secreted proteins that act locally in a paracrine or autocrine fashion to regulate essential cellular activities. This group includes the FGF1, FGF4, FGF7, FGF8, and FGF9 subfamilies, which require heparin or heparan sulfate proteoglycans as cofactors to bind and activate their cognate Fibroblast Growth Factor Receptors (FGFRs) (Ornitz & Itoh, 2015, PubMed: 25743612). They play pivotal roles in embryonic development, including mesoderm induction and organogenesis, as well as in adult physiology for tissue repair, wound healing, and angiogenesis (Beenken & Mohammadi, 2009, PubMed: 19247304). In disease states, over-expression or mutations in these ligands can lead to uncontrolled cell growth in various cancers or contribute to fibrotic disorders and skeletal dysplasias (Turner & Grose, 2010, PubMed: 20168337). Furthermore, the specificity of FGF-FGFR interactions is governed by the tissue-specific expression of receptor isoforms and the presence of specific heparan sulfate motifs, making the system a complex but precise regulatory network (Zhang et al., 2006, PubMed: 16597617). Therapeutic interventions targeting these ligands include recombinant proteins for regenerative medicine, such as Palifermin for oral mucositis, and ligand traps like FP-1039 designed to sequester FGFs and inhibit tumor progression (Katoh, 2016, PubMed: 27161358).

Other names

Paracrine Fibroblast Growth FactorsHeparin-binding growth factors (HBGFs)FGF1 subfamilyFGF4 subfamilyFGF7 subfamilyFGF8 subfamilyFGF9 subfamily

Canonical FGFs bind to and activate Fibroblast Growth Factor Receptors (FGFR1-4) in a heparin-dependent manner, triggering intracellular signaling cascades such as the RAS-MAPK, PI3K-AKT, and PLCγ pathways to regulate gene expression and cellular behavior (Ornitz & Itoh, 2015, PubMed: 25743612).